尽管上述问题存在不确定性，公司仍将继续竭尽全力获取必要的审核资料，并与相关各方及其核数师紧 密合作，以及时解决所有未决问题及制定时间表以便于实际可行情况下尽快落实及刊发2024年经审核全 年业绩，公司争取于2025年5月底前完成。由于进一步延迟刊发2024年经审核全年业绩，董事会会议亦 将相应推迟。 智通财经APP讯，弘海高新资源(00065)发布公告，如先前公告所披露，集团与老挝公司的当地管理层及 业务伙伴在集团财务报告及审核要求方面存在沟通障碍，及公司于2025年3月透过其香港法律顾问向老 挝泰山久久投资贸易有限公司(泰山久久投资)的法定代表人及业务伙伴(收件人)发出催促函。 于2025年4月14日，公司透过其老挝法律顾问于老挝境内向收件人发出进一步催促函，要求(其中包括) 提供所要求的财务资料及文件，并与公司核数师充分合作。截至本公告日期，公司仍在等待老挝公司及 收件人的回应。 公司现正积极寻求老挝法律顾问有关可于老挝强制执行的任何适用法律行动的进一步法律意见，以行使 其作为老挝公司主要股东的权利，包括但不限于变更及替换当地管理层以接管老挝公司的所有相关账册 及记录，提出调解，向地方当局上报问题及╱或向 ...

Core Viewpoint - The recent developments surrounding Innovent Biologics' core product, Ivosidenib, have generated significant market interest, particularly following its positive clinical trial results against the leading PD-1 inhibitor, Keytruda [2][3]. Group 1: Clinical Trial Results - Ivosidenib's new indication for non-small cell lung cancer (NSCLC) has been approved by the National Medical Products Administration (NMPA) in China, based on the HARMONi-2 clinical trial data [2][5]. - The HARMONi-2 trial demonstrated a median progression-free survival (PFS) of 11.14 months for Ivosidenib compared to 5.82 months for Keytruda, with a hazard ratio (HR) of 0.51, indicating a 49% reduction in the risk of disease progression or death [5][9]. - The overall survival (OS) analysis showed an HR of 0.777, suggesting a 22.3% reduction in the risk of death, which is close to the FDA's threshold for approval [5][6][7]. Group 2: Market Reactions - Following the announcement of the OS data, shares of Summit, Ivosidenib's overseas partner, fell nearly 36%, while Innovent's stock dropped by 11% [3]. - The market's reaction reflects concerns over the OS data's adequacy for U.S. approval, despite the positive PFS results [3][7]. Group 3: Regulatory Insights - The FDA requires that for OS to be a primary endpoint in clinical trials, the HR must be less than 0.8 for approval, which Ivosidenib's data nearly meets [6][9]. - Innovent's strategy involved designing the HARMONi-2 trial with PFS as the primary endpoint, aligning with regulatory expectations while still aiming for OS data to support future approvals [8][9]. Group 4: Industry Impact - The results from the HARMONi-2 trial are seen as a significant milestone in the field of cancer immunotherapy, potentially reshaping treatment standards for NSCLC [11][12]. - The ongoing HARMONi-7 trial aims to further validate Ivosidenib's efficacy in a larger patient population, with plans to enroll nearly 800 patients [13].

凯升控股公告，公司直接全资附属公司SA Investments认购Suntrust之新可换股债券，票息率为零，本金 总额最多为135.11亿菲律宾比索。SA Investments与Suntrust于2025年4月30日订立新可换股债券认购协议 之第二份补充协议，将最后截止日期由2025年4月30日下午五时正延期至2025年8月31日下午五时正。新 可换股债券认购协议的其他条款及条件均维持不变。Suntrust已向证券交易委员会作出申请，取得证券 交易委员会之确认将需时额外约4个月。公司股份自2024年2月14日起暂停买卖，将继续暂停买卖直至符 合所有复牌指引。 ...

Core Viewpoint - The increasing emphasis on sustainable development and the expanding influence of ESG (Environmental, Social, and Governance) in the plastic pipe industry, with China Liansu's 2024 Sustainable Development Report highlighting its achievements and commitment to green transformation [1][2]. Group 1: ESG as a Key Focus - ESG is considered a "must-answer question" for the plastic pipe industry, with significant carbon emissions from the construction sector, making plastic pipes crucial for carbon reduction [2]. - The plastic pipe industry supports urbanization and rural revitalization, emphasizing its role in the national economy and the need for sustainable development [2]. - The industry is transitioning from rapid expansion to stable development, necessitating improved governance structures and innovation to enhance supply chain stability [2]. Group 2: China Liansu's Green Initiatives - In 2024, China Liansu generated 56.55 million kWh of solar power, saving approximately 39.89 million RMB in electricity costs, recycled 5.26 million tons of water, and recovered 160,389 tons of plastic [3]. - The company integrates ESG principles into product development, achieving certifications for multiple products, including 15 pipeline products recognized as green building materials [3]. - China Liansu is enhancing its market presence in environmental protection and technology development, with a waste acid resource utilization base processing 215,000 tons annually [3]. Group 3: Future Goals and Innovations - By 2025, China Liansu aims to reduce greenhouse gas emissions intensity by 3% compared to 2021, control hazardous waste generation to below 1.1 kg/ton, and manage total water consumption intensity below 1.60 tons/ton [4]. - The company has established a trend of innovation-driven growth, with significant technological advancements in various product lines, enhancing its market competitiveness [6]. - China Liansu is fostering a sustainable supply chain, recognized as a national-level green supply chain management enterprise, with a total of 22,751 suppliers [7]. Group 4: Societal Contributions and Internal Governance - The company contributes to national strategies, such as rural revitalization, by supporting agricultural projects, which enhances its market presence and demonstrates its product capabilities [7]. - China Liansu emphasizes employee welfare and governance, establishing performance evaluation systems to respect and motivate employees, aiming for mutual growth [7]. Group 5: Investment Potential - From a value investment perspective, China Liansu is recognized as a high-quality ESG target within the plastic pipe industry, attracting increased investor interest [8].

智通财经APP讯，港誉智慧城市服务(00265)发布公告，于2025年4月30日，本公司与东胜房地产订立抵 销协议，本公司已有条件同意以接纳东胜房地产向本公司或指定实体转让该等物业的方式，抵销部分未 结应收款。 由于东胜房地产未能及时结算未结应收款、经本集团多次要求付款，并探讨不同措施以收回未结应收款 后，本公司与东胜房地产同意订立抵销安排。未结应收款来自本集团过往向东胜房地产及/或其关连公 司提供的物业管理;及推广、活动策划及咨询服务。本公司已採取多项措施，以追讨未结应收款，包括 定期以口头及电子方式要求付款，以及组织实体会议。经不断努力，本公司与东胜房地产最终同意将该 等物业转让予本公司或指定实体，作为未结应收款的部分结算。本集团正探讨其余方案，以收回未结应 收款的余额。 除抵销安排外，东胜房地产自2025年1月1日起已以现金结算合共约人民币87万元(相当于约92万港元)。 于紧随完成日期后，未结应收款将减少至约人民币4271万元(相当于约4527万港元)。 本公司已考虑与抵销安排有关的风险。根据抵销协议的条款，倘任何先决条件未能于最后截止日期当日 或之前达成，则本公司有权撤销抵销协议。 董事认为，通过订 ...

证券时报·数据宝统计，中裕能源在港交所公告显示，4月30日以每股4.270港元至4.340港元的价格回购 100.00万股，回购金额达428.99万港元。该股当日收盘价4.290港元，上涨0.47%，全天成交额704.56万 港元。 自4月24日以来公司已连续5日进行回购，合计回购500.00万股，累计回购金额2158.76万港元。 其间该 股累计上涨0.23%。 今年以来该股累计进行26次回购，合计回购2739.00万股，累计回购金额1.17亿港元。（数据宝） | 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2025.04.30 | 100.00 | 4.340 | 4.270 | 428.99 | | 2025.04.29 | 100.00 | 4.310 | 4.280 | 429.61 | | 2025.04.28 | 100.00 | 4.400 | 4.340 | 437.24 | | 2025.04.25 | 100.00 | 4.390 | 4.300 | 434.6 ...

执行董事、首席执行官兼联席主席秦兴华表示，集团积极践行绿色理念，全力推动「绿色运输」「绿色 包装」「绿色园区」和「绿色办公」实践。2024年，加大与战略伙伴的合作力度，加快新能源重卡的应 用步伐，通过LNG车辆替代柴油车型、自营产业园光伏板安装等举措，积极探索清洁能源应用新路 径。以实际行动引领行业绿色低碳转型，为社会可持续发展贡献专业力量。 秦兴华进一步强调，2024年，集团持续加大科技投入，将数字化系统深度融入全链路运营。作为零担行 业首个落地运营自动驾驶重卡的企业，集团不断探索智慧技术应用边界。通过销售、运营、客服三位一 体的「铁三角」团队的一体化、数字化协同，实现快速响应机制。同时，逐步部署分拨自动化流水线， 进一步推动快运行业「新质生产力」落地。通过创新实践，集团在提升服务效能的同时降低了运营成 本，实现了效率与成本的平衡，助力集团与合作伙伴实现共赢发展、降本增效。 报告显示，集团秉持「网络覆盖最密、成本最优、品质最好、时效最稳、服务响应最快」的「五最」战 略目标，通过数字化与智能化科技手段的深度应用，不仅为传统物流网络注入新动能，更为行业革新与 可持续发展提供了强有力的支持。 今日，安能物流(99 ...

持续提升海外举办三所大学的人才培养质量，马来西亚英迪国际大学2025年QS世界大学排名位列516 位;泰国西那瓦国际大学荣登2025年QS世界大学学科排名 — 艺术与设计学科榜单，位列第151–200名区 间。积极推进公司举办的海外院校与境内院校优质教育资源共享，九个中外合作办学项目顺利推进，联 合培养人才工作取得新成果。 智通财经APP讯，希教国际控股(01765)发布截至2025年2月28日止六个月的中期业绩，收入21.17亿元 (人民币，下同)，同比增加3.65%;股东应占溢利3.07亿元，同比增加37.36%;每股基本盈利0.037元。 集团围绕精准引才、长效育才，扎实推进人才引进与培养工作。报告期内，各院校新引进393名教师， 其中高层次人才佔比达18.6%;开展各类教师培训1,558场次;教师参加竞赛获奖800项，其中国家级奖56 项、省级奖398项。 公告称，集团持续加大院校实训资源建设投入，全面提升实践教学条件。报告期内，公司投入资金近亿 元人民币用于实训场地扩建、软硬件设备升级、教学环境改造等，新建实训室超过40间;本期瞄准新质 生产力发展对人才的需求，各院校申报无人机、工业机器人技术、人工 ...

Core Insights - Yum China Holdings, Inc. reported strong Q1 2025 results driven by efficiency and innovation, achieving an overall operating profit margin of 13.4% and same-store sales growth for nine consecutive quarters [1] Group 1: Financial Performance - The total number of stores reached 16,642 by the end of March, leading the restaurant industry in China [1] - KFC's system sales increased by 3% year-over-year, attributed to innovative product offerings [3] - Pizza Hut's system sales grew by 2% year-over-year, with a significant 17% increase in same-store sales [3] Group 2: Brand Strategy and Consumer Engagement - KFC's innovative approach included launching a spicy version of its classic chicken to celebrate its 85th anniversary, successfully blending Western and Chinese flavors [3] - Pizza Hut's strategy focused on cost control and revenue enhancement, exemplified by its 35th-anniversary promotion of the Super Supreme Pizza [3] - Membership numbers exceeded 540 million, with 66% of revenue coming from member purchases, indicating strong brand loyalty [4] Group 3: Expansion and Innovation - KFC's coffee brand, K Coffee, opened 1,000 stores in two years, with plans to reach 1,500 by the end of 2025, targeting young consumers with affordable premium coffee [5] - Pizza Hut's WOW model is expanding into lower-tier markets, appealing to a broader consumer base with a flexible and low-cost approach [5] Group 4: Technological Integration - The company utilizes AI technology across various operational aspects, achieving a 90% resolution rate for customer complaints through AI-driven customer service [7] - Yum China plans to open 1,600 to 1,800 new stores in 2025, demonstrating resilience and commitment to growth despite market changes [7]

Core Viewpoint - 康方生物's new indication for依沃西单抗 has been approved by the National Medical Products Administration (NMPA) for first-line treatment of PD-L1 positive non-small cell lung cancer (NSCLC), based on positive results from the HARMONi-2 clinical trial [1][2]. Group 1: Clinical Trial Results - In the HARMONi-2 trial, the median progression-free survival (PFS) for the依沃西 group was 11.14 months, compared to 5.82 months for the帕博利珠 group, with a hazard ratio (HR) of 0.51, indicating a 49% reduction in the risk of disease progression or death [2]. - The interim analysis for overall survival (OS) showed a HR of 0.777, reflecting a 22.3% reduction in the risk of death for the依沃西 group compared to the帕博利珠 group [2]. Group 2: Market Reaction - Despite the positive clinical data,康方生物's stock fell over 19% on April 28, closing at 87.20 HKD per share, while its partner Summit's stock dropped more than 36% [3]. - Market sentiment suggests that while依沃西 shows clinical benefits compared to帕博利珠, it did not achieve the statistical significance expected by investors, as帕博利珠 has shown greater risk reductions in OS in previous trials [3]. Group 3: Company Perspective - 康方生物's CEO,夏瑜, stated that the market's interpretation of the data is somewhat misaligned, emphasizing that OS was not the primary endpoint of the study and that the low maturity of the OS data (39%) was intended to show a trend of benefit [3][4]. - The company designed the HARMONi-2 trial to focus on PFS as the primary endpoint, with the aim of obtaining approval for the first-line NSCLC indication in China [4].